We can’t show the full text here under this license. Use the link below to read it at the source.
US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Number of U.S. adults with type 2 diabetes who could benefit from semaglutide to prevent heart disease
AI simplified
Abstract
Semaglutide may prevent over 75,000 (CVD) events annually among eligible US adults with (T2DM).
- Among 4755 adults with T2DM, 1132 individuals (6.9 million projected) met the SUSTAIN-6 eligibility criteria.
- The estimated preventable CVD events include 75,681 primary outcome events and 128,329 expanded composite events.
- Additional preventable events include 72,390 combined nonfatal heart attacks, nonfatal strokes, and all-cause deaths.
- The analysis suggests 36,195 non-fatal strokes and 85,552 revascularizations could also be avoided annually.
- The population analyzed had a higher representation of female and black patients, shorter diabetes duration, and fewer prior CVD cases compared to SUSTAIN-6.
AI simplified
Key numbers
6.9 million
Eligible US Adults with
Projected number of adults meeting criteria.
75,681
Preventable Primary Composite Events
Estimated annual preventable events if treated with semaglutide.
58,000
Preventable Events in Males
Estimated annual preventable events for males compared to females.